Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:trametinib
go back to main search page
Accession:CHEBI:75998 term browser browse the term
Definition:A pyridopyrimidine that is used (as its dimethyl sulfoxide addition compound) for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, and who have not received prior BRAF inhibitor treatment.
Synonyms:exact_synonym: N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide
 related_synonym: Formula=C26H23FIN5O4;   GSK 1120212;   InChI=1S/C26H23FIN5O4/c1-13-22-21(23(31(3)24(13)35)30-20-10-7-15(28)11-19(20)27)25(36)33(17-8-9-17)26(37)32(22)18-6-4-5-16(12-18)29-14(2)34/h4-7,10-12,17,30H,8-9H2,1-3H3,(H,29,34);   InChIKey=LIRYPHYGHXZJBZ-UHFFFAOYSA-N;   JTP 74057;   SMILES=CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O;   trametinibum
 xref: CAS:871700-17-3;   DrugBank:DB08911;   Drug_Central:4802;   KEGG:D10175;   LINCS:LSM-1143
 xref_mesh: MESH:C560077
 xref: PMID:21523318;   PMID:22245957;   PMID:23035153;   PMID:23237773;   PMID:23248257;   PMID:23290787;   PMID:23432625;   PMID:23438367;   PMID:23441129;   PMID:23533766;   PMID:23583440;   PMID:23587417;   PMID:23649971;   PMID:23658559;   PMID:23709751;   PMID:23807941;   PMID:23844038;   PMID:23846731;   PMID:23893461;   PMID:23971497;   PMID:23977666;   PMID:24055054;   Patent:WO2005121142;   Patent:WO2011038082;   Patent:WO2011038085;   Patent:WO2011047238;   Reaxys:12497153;   Wikipedia:Trametinib


show annotations for term's descendants           Sort by:
 
trametinib term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Acaca acetyl-CoA carboxylase alpha multiple interactions ISO trametinib affects the reaction [[BRAF protein affects the susceptibility to Vemurafenib] which affects the expression of ACACA mRNA] CTD PMID:29950559 NCBI chr10:71,519,392...71,719,910
Ensembl chr10:71,536,533...71,719,910
JBrowse link
G Acly ATP citrate lyase multiple interactions ISO trametinib affects the reaction [[BRAF protein affects the susceptibility to Vemurafenib] which affects the expression of ACLY mRNA] CTD PMID:29950559 NCBI chr10:88,392,248...88,442,845
Ensembl chr10:88,392,248...88,442,845
JBrowse link
G Akt1 AKT serine/threonine kinase 1 increases phosphorylation
multiple interactions
ISO trametinib results in increased phosphorylation of AKT1 protein
[omipalisib co-treated with trametinib] results in decreased phosphorylation of AKT1 protein
CTD PMID:22733540 NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
JBrowse link
G Appl1 adaptor protein, phosphotyrosine interacting with PH domain and leucine zipper 1 multiple interactions ISO trametinib inhibits the reaction [Poly I-C results in increased degradation of APPL1 protein] CTD PMID:25780039 NCBI chr16:2,560,103...2,602,035
Ensembl chr16:2,563,520...2,602,103
JBrowse link
G Bcl2l11 BCL2 like 11 multiple interactions
increases expression
ISO [trametinib co-treated with omipalisib] results in increased expression of BCL2L11 protein
trametinib results in increased expression of BCL2L11 protein
CTD PMID:22733540 NCBI chr 3:120,726,906...120,764,192
Ensembl chr 3:120,726,906...120,764,192
JBrowse link
G Braf B-Raf proto-oncogene, serine/threonine kinase multiple interactions ISO betulin affects the reaction [BRAF protein affects the susceptibility to [dabrafenib co-treated with trametinib]]; BRAF protein affects the reaction [[APS-2-79 results in increased susceptibility to trametinib] which results in increased phosphorylation of MAPK1 protein]; BRAF protein affects the reaction [[APS-2-79 results in increased susceptibility to trametinib] which results in increased phosphorylation of MAPK3 protein]; BRAF protein affects the susceptibility to [dabrafenib co-treated with trametinib]; fatostatin affects the reaction [BRAF protein affects the susceptibility to [dabrafenib co-treated with trametinib]]; trametinib affects the reaction [[BRAF protein affects the susceptibility to Vemurafenib] which affects the cleavage of SREBF1 protein]; trametinib affects the reaction [[BRAF protein affects the susceptibility to Vemurafenib] which affects the expression of ACACA mRNA]; trametinib affects the reaction [[BRAF protein affects the susceptibility to Vemurafenib] which affects the expression of ACLY mRNA]; trametinib affects the reaction [[BRAF protein affects the susceptibility to Vemurafenib] which affects the expression of FASN mRNA]; trametinib affects the reaction [[BRAF protein affects the susceptibility to Vemurafenib] which affects the phosphorylation of MAPK1 protein]; trametinib affects the reaction [[BRAF protein affects the susceptibility to Vemurafenib] which affects the phosphorylation of MAPK3 protein] CTD PMID:27556948, PMID:29950559 NCBI chr 4:67,389,331...67,520,549
Ensembl chr 4:67,396,192...67,520,356
JBrowse link
G Casp3 caspase 3 multiple interactions ISO [GNAQ gene mutant form results in increased susceptibility to [trametinib co-treated with omipalisib]] which results in increased cleavage of CASP3 protein CTD PMID:22733540 NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
JBrowse link
G Casp7 caspase 7 multiple interactions ISO [GNAQ gene mutant form results in increased susceptibility to [trametinib co-treated with omipalisib]] which results in increased cleavage of CASP7 protein CTD PMID:22733540 NCBI chr 1:277,190,557...277,242,779
Ensembl chr 1:277,190,964...277,242,774
JBrowse link
G Ccl5 C-C motif chemokine ligand 5 multiple interactions ISO trametinib promotes the reaction [Lipopolysaccharides results in increased expression of CCL5 mRNA]; trametinib promotes the reaction [Poly I-C results in increased expression of CCL5 mRNA] CTD PMID:25780039 NCBI chr10:70,739,764...70,744,303
Ensembl chr10:70,739,800...70,744,315
JBrowse link
G Cxcl10 C-X-C motif chemokine ligand 10 multiple interactions ISO trametinib promotes the reaction [Lipopolysaccharides results in increased expression of CXCL10 mRNA]; trametinib promotes the reaction [Poly I-C results in increased expression of CXCL10 mRNA] CTD PMID:25780039 NCBI chr14:17,210,733...17,212,930
Ensembl chr14:17,210,733...17,212,930
JBrowse link
G Fasn fatty acid synthase multiple interactions ISO trametinib affects the reaction [[BRAF protein affects the susceptibility to Vemurafenib] which affects the expression of FASN mRNA] CTD PMID:29950559 NCBI chr10:109,987,735...110,005,901
Ensembl chr10:109,987,735...110,005,901
JBrowse link
G Gna11 G protein subunit alpha 11 increases response to substance ISO GNA11 protein mutant form results in increased susceptibility to trametinib CTD PMID:22733540 NCBI chr 7:11,033,400...11,047,284
Ensembl chr 7:11,033,317...11,047,437
JBrowse link
G Gnaq G protein subunit alpha q multiple interactions
increases response to substance
ISO [GNAQ gene mutant form results in increased susceptibility to [trametinib co-treated with omipalisib]] which results in increased cleavage of CASP3 protein; [GNAQ gene mutant form results in increased susceptibility to [trametinib co-treated with omipalisib]] which results in increased cleavage of CASP7 protein; GNAQ gene mutant form results in increased susceptibility to [trametinib co-treated with omipalisib]
GNAQ protein mutant form results in increased susceptibility to trametinib
CTD PMID:22733540 NCBI chr 1:233,382,778...233,622,584
Ensembl chr 1:233,382,708...233,622,786
JBrowse link
G Ifnb1 interferon beta 1 multiple interactions ISO trametinib promotes the reaction [Lipopolysaccharides results in increased expression of IFNB1 mRNA]; trametinib promotes the reaction [Poly I-C results in increased expression of IFNB1 mRNA] CTD PMID:25780039 NCBI chr 5:106,865,192...106,865,746
Ensembl chr 5:106,865,192...106,865,746
JBrowse link
G Irf3 interferon regulatory factor 3 multiple interactions ISO trametinib promotes the reaction [Lipopolysaccharides results in increased phosphorylation of IRF3 protein] CTD PMID:25780039 NCBI chr 1:100,992,244...100,997,202
Ensembl chr 1:100,992,405...100,997,198
JBrowse link
G Jun Jun proto-oncogene, AP-1 transcription factor subunit multiple interactions ISO [omipalisib co-treated with trametinib] results in increased phosphorylation of JUN protein; JUN results in decreased susceptibility to [omipalisib co-treated with trametinib] CTD PMID:22733540 NCBI chr 5:114,011,184...114,014,277
Ensembl chr 5:114,011,189...114,014,277
JBrowse link
G Map2k1 mitogen activated protein kinase kinase 1 decreases response to substance
multiple interactions
ISO MAP2K1 protein mutant form results in decreased susceptibility to trametinib
[MAP2K1 protein mutant form results in decreased susceptibility to trametinib] inhibits the reaction [trametinib results in decreased phosphorylation of MAPK1 protein]; [MAP2K1 protein mutant form results in decreased susceptibility to trametinib] inhibits the reaction [trametinib results in decreased phosphorylation of MAPK3 protein]
CTD PMID:29768711 NCBI chr 8:69,134,218...69,722,573
Ensembl chr 8:69,134,223...69,164,758
JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions
decreases phosphorylation
ISO [APS-2-79 results in increased susceptibility to trametinib] which results in increased phosphorylation of MAPK1 protein; [MAP2K1 protein mutant form results in decreased susceptibility to trametinib] inhibits the reaction [trametinib results in decreased phosphorylation of MAPK1 protein]; [omipalisib co-treated with trametinib] results in decreased phosphorylation of MAPK1 protein; BRAF protein affects the reaction [[APS-2-79 results in increased susceptibility to trametinib] which results in increased phosphorylation of MAPK1 protein]; trametinib affects the reaction [[BRAF protein affects the susceptibility to Vemurafenib] which affects the phosphorylation of MAPK1 protein]
trametinib inhibits the reaction [camostat results in increased phosphorylation of MAPK1 protein]; trametinib inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK1 protein]; trametinib inhibits the reaction [Poly I-C results in increased phosphorylation of MAPK1 protein]
CTD PMID:22733540, PMID:25104499, PMID:25780039, PMID:27556948, PMID:29768711, PMID:29950559 NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions
decreases phosphorylation
ISO [APS-2-79 results in increased susceptibility to trametinib] which results in increased phosphorylation of MAPK3 protein; [MAP2K1 protein mutant form results in decreased susceptibility to trametinib] inhibits the reaction [trametinib results in decreased phosphorylation of MAPK3 protein]; [omipalisib co-treated with trametinib] results in decreased phosphorylation of MAPK3 protein; BRAF protein affects the reaction [[APS-2-79 results in increased susceptibility to trametinib] which results in increased phosphorylation of MAPK3 protein]; trametinib affects the reaction [[BRAF protein affects the susceptibility to Vemurafenib] which affects the phosphorylation of MAPK3 protein]
trametinib inhibits the reaction [camostat results in increased phosphorylation of MAPK3 protein]; trametinib inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK3 protein]; trametinib inhibits the reaction [Poly I-C results in increased phosphorylation of MAPK3 protein]
CTD PMID:22733540, PMID:25104499, PMID:25780039, PMID:27556948, PMID:29768711, PMID:29950559 NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
JBrowse link
G Myc MYC proto-oncogene, bHLH transcription factor decreases expression ISO trametinib results in decreased expression of MYC protein CTD PMID:22733540 NCBI chr 7:102,586,313...102,591,240
Ensembl chr 7:102,586,313...102,591,240
JBrowse link
G Rb1 RB transcriptional corepressor 1 decreases phosphorylation ISO trametinib results in decreased phosphorylation of RB1 protein CTD PMID:22733540 NCBI chr15:55,081,582...55,209,060
Ensembl chr15:55,083,140...55,209,342
JBrowse link
G Rps6kb1 ribosomal protein S6 kinase B1 decreases phosphorylation ISO trametinib results in decreased phosphorylation of RPS6KB1 protein CTD PMID:22733540 NCBI chr10:73,824,200...73,865,503
Ensembl chr10:73,824,202...73,865,364
JBrowse link
G Srebf1 sterol regulatory element binding transcription factor 1 multiple interactions ISO trametinib affects the reaction [[BRAF protein affects the susceptibility to Vemurafenib] which affects the cleavage of SREBF1 protein] CTD PMID:29950559 NCBI chr10:46,570,996...46,593,021
Ensembl chr10:46,570,996...46,593,009
JBrowse link

Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 19785
    role 19732
      biological role 19732
        antimicrobial agent 17309
          antiviral agent 10245
            anticoronaviral agent 8940
              trametinib 23
                trametinib dimethyl sulfoxide 0
Path 2
Term Annotations click to browse term
  CHEBI ontology 19785
    subatomic particle 19782
      composite particle 19782
        hadron 19782
          baryon 19782
            nucleon 19782
              atomic nucleus 19782
                atom 19782
                  main group element atom 19670
                    p-block element atom 19670
                      carbon group element atom 19572
                        carbon atom 19561
                          organic molecular entity 19561
                            organic group 18493
                              organic divalent group 18486
                                organodiyl group 18486
                                  carbonyl group 18389
                                    carbonyl compound 18389
                                      carboxylic acid 18060
                                        carboacyl group 17346
                                          univalent carboacyl group 17346
                                            carbamoyl group 17132
                                              carboxamide 17132
                                                acetamides 12380
                                                  trametinib 23
                                                    trametinib dimethyl sulfoxide 0
paths to the root

NHLBI Logo

RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.